Table 2 Patient cohort characteristics for RP group and LDR group for patients with biochemical recurrence and patients without biochemical recurrence
Parameters | recurrence(n = 88) | Non-recurrence(n = 273) |
|---|---|---|
Treatment modality | ||
 RP | 46 | 114 |
 LDR | 42 | 159 |
Age (years) | ||
 Median | 68 | 61 |
 Range | 48–81 | 41–74 |
Initial PSA (ng/ml) | ||
 Median | 11.8 | 12.3 |
 Range | 4.45–20.2 | 0.83–19..73 |
Treatment modality | n, % | |
 RP | 46 (52.3%) | 114 (41.8%) |
 LDR | 42 (47.7%) | 159 (58.2%) |
Clinical stage | n, % | |
 T1c | 7 (7.9%) | 50 (18.3%) |
 T2a | 15 (17.0%) | 61 (22.3%) |
 T2b | 17 (19.3%) | 56 (20.5%) |
 T2c | 49 (55.6%) | 106 (38.8%) |
PPBC | n, % | |
  ≤ 50% | 52 (59.9%) | 227 (83.1%) |
  > 50% | 36 (40.9%) | 46 (16.8%) |
Gleason Score | n, % | |
 6(3 + 3) | 45 (51.1%) | 109 (39.9%) |
 7(3 + 4) | 27 (30.6%) | 90 (32.9%) |
 7(4 + 3) | 16 (18.1%) | 74 (25.2%) |
Prostate volume(ml) | n, % | |
  ≤ 30 | 58 65.9%) | 77 (28.2%) |
  > 30 | 30 (34.0%) | 196 (71.8%) |
Risk | n, % | |
 Favorable | 18 (20.45%) | 71 (26.0%) |
 Unfavorable | 70 (79.5%) | 202 (73.9%) |
Metastasis status | n, % | |
 Positive | 17 (19.3%) | 1 (0.4%) |
 Negative | 71 (80.6%) | 272 (99.6%) |